By the way, has PPHM offered hints as to whether there is a difference in OS in the 1st line NSCLC trial? The CEO stated they expected to report MOS data for this trial and their pancreatic cancer trial by EOY. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77733376